Skip to main content
. 2023 Feb 8;12(4):547. doi: 10.3390/cells12040547

Figure 2.

Figure 2

Erlotinib and MLN0128 treatment synergistically impacts growth-promoting pathways in EGFR-driven GBMs. (a) Antibody array with 45 cellular phosphor-kinases was used to detect pathways impacted by erlotinib and MLN0128. GBM192 cells were treated with erlotinib (20 μM), MLN0128 (1 μM), or the combination of the two drugs for 24 h. The arrays were scanned and quantified, using the control (darkest spots) for normalization. 1-p-ERK; 2-p-AKT, 3-p-Ras40, 4-p-EGFR. (b) Quantification of the levels of phosphokinases under each treatment condition. Units represent normalized densitometry values. (c–e) Western blot analyses of the same phosphoproteins were performed in PDXCs from GBM192, GBM197, and GBM218 treated with vehicle (DMSO), erlotinib, MLN0128, or the combination of the two drugs and probed with the indicated antibodies. GAPDH was used to control for equal protein loading.